Analysts' Top 5 Price Targets of March 12, 2025
Reading Time: 2 minutes
Rocket Pharmaceuticals [US77313F1066]: BMO Capital starts coverage with an Overweight rating and a price target of $50 (472% upside potential) BMO's experts positively highlight Rocket's gene therapies, as these therapies differ from competing gene therapy approaches. Rocket's gene therapies target the heart and are expected to have a lifelong impact. Additionally, the company's programs focus on diseases for which there are limited or no treatment options. One main program targets Danon disease, a severe cardiomyopathy that leads to early death...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
